# Semaglutide Domain - Strategic Plan

## Purpose

Apply Domain-Driven Design principles to semaglutide therapy systems, creating a domain model that captures the clinical, pharmacological, and operational complexity of GLP-1 receptor agonist treatment programs. The model serves as a shared foundation for endocrinologists, obesity medicine specialists, pharmacists, payers, and software developers to communicate using a ubiquitous language aligned with evidence-based prescribing and monitoring practices.

## Goals

1. Establish a ubiquitous language that bridges clinical pharmacology, patient management, and software modeling for semaglutide therapy.
2. Define six bounded contexts reflecting the natural divisions of semaglutide prescribing, dispensing, and monitoring.
3. Model the dosing and titration lifecycle as a state machine with clinically validated transitions and safety guardrails.
4. Capture the dual-indication nature of semaglutide (type 2 diabetes and chronic weight management) as distinct treatment pathways with shared pharmacological foundations.
5. Address regulatory compliance (FDA labeling, pharmacovigilance requirements) and payer authorization workflows within the domain model.

## Scope

### In Scope

- Patient eligibility assessment and enrollment into semaglutide therapy
- Dose titration protocols for both subcutaneous and oral formulations
- Clinical outcome tracking (glycemic control, weight loss, cardiovascular markers)
- Adverse event identification, grading, and regulatory reporting
- Pharmacy operations including specialty pharmacy and cold chain logistics
- Insurance prior authorization and patient assistance programs

### Out of Scope

- General endocrinology or obesity medicine beyond semaglutide-specific workflows
- Other GLP-1 receptor agonist medications (liraglutide, tirzepatide) unless for comparison
- Bariatric surgery pathways
- Primary care diabetes management unrelated to semaglutide
- Drug manufacturing and clinical trial operations

## Approach

### Phase 1: Foundation
- Define ubiquitous language across all bounded contexts.
- Document strategic design patterns and subdomain classification.
- Establish context map showing relationships between clinical, pharmacy, and regulatory contexts.

### Phase 2: Tactical Modeling
- Model aggregates, entities, and value objects within each bounded context.
- Define domain events that trigger cross-context workflows (e.g., dose escalation triggers adverse event monitoring adjustment).
- Design repositories and domain services for treatment lifecycle management.

### Phase 3: Integration
- Design event-driven architecture for cross-context communication.
- Define anti-corruption layers for external system integration (EHR, pharmacy benefit managers, FDA reporting systems).
- Document integration patterns between clinical and operational contexts.

### Phase 4: Compliance and Pharmacovigilance
- Map FDA label requirements to domain model constraints.
- Incorporate REMS and post-market surveillance obligations into domain events.
- Validate domain model against clinical trial protocols (STEP, SUSTAIN, SELECT).

## Milestones

- [ ] Ubiquitous language defined and reviewed by clinical pharmacology experts
- [ ] All six bounded contexts documented with boundaries and responsibilities
- [ ] Context map completed showing inter-context relationships
- [ ] Tactical patterns modeled for each bounded context
- [ ] Domain events identified and cross-context workflows documented
- [ ] Integration patterns defined for EHR, pharmacy, and regulatory systems
- [ ] FDA labeling and pharmacovigilance requirements mapped to domain invariants
- [ ] Documentation reviewed for clinical and regulatory accuracy

## References

- Evans, E. (2003). Domain-Driven Design: Tackling Complexity in the Heart of Software. Addison-Wesley.
- Vernon, V. (2013). Implementing Domain-Driven Design. Addison-Wesley.
- Khononov, V. (2021). Learning Domain-Driven Design. O'Reilly Media.
- Wilding, J. P. H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.
- Marso, S. P. et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.
